COVID-19 (SARS-CoV-2) ELISAs
IgG, IgA, IgM

Our novel COVID-19 (SARS-CoV-2) ELISAs are serological assays for the qualitative determination of antibodies *(IgA, IgG and IgM)* against SARS-CoV-2 in human serum or plasma. They enable the assessment of the immune response of patients during and after the infection and allow the collection of epidemiological data.

Following characteristics come along with these kits:

- highly conserved recombinant SARS-CoV-2 nucleocapsid protein is used as antigen
- suitable for open automated ELISA systems
- CE-marked
- fast results (< 2 hours)
- separate detection of IgG, IgA and IgM antibodies
- multilingual IFU

ELISA as ideal tool for screening

Serological tests for SARS-CoV-2 are increasingly important to obtain an accurate picture of the number of COVID-19 cases. It is crucial to identify individuals who have already developed antibodies against the virus even if it is not yet clear whether reinfection is possible. This question as well as others like those about herd immunity can also be investigated with the help of serological tests.

Demeditec COVID-19 (SARS-CoV-2) ELISAs

Product	Cat.-No.	State of Infection
COVID-19 (SARS-CoV-2) IgA	DECOV1902	found in mucosal membranes: ➜ first line of defence, especially for respiratory pathogens produced in early stage of the disease: ➜ seems to be more pronounced than IgM
COVID-19 (SARS-CoV-2) IgM	DECOV1903	primary antibody response ➜ suggests a current or very recent infection
COVID-19 (SARS-CoV-2) IgG	DECOV1901	secondary antibody response; follows IgM production High IgG titer with low IgM titer: ➜ may indicate past infection